首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin metronidazole and ornidazole.
【2h】

Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin metronidazole and ornidazole.

机译:喹诺酮类药物与克林霉素甲硝唑和奥硝唑合用时的药代动力学和血清杀菌活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To enhance the antimicrobial spectrum of the quinolones against anaerobic organisms and gram-positive bacteria, we investigated in two studies the parenteral combinations of ciprofloxacin (200 mg) and ofloxacin (200 mg) with metronidazole (500 mg) or clindamycin (600 mg) and the oral combinations of enoxacin (400 mg) and fleroxacin (400 mg) with metronidazole (400 mg), clindamycin (300 mg), or ornidazole (500 mg) (only with fleroxacin). The pharmacokinetics and serum bactericidal activities (SBAs) against 5 aerobic and 2 anaerobic species (total, 58 strains) were determined in two groups of 10 healthy volunteers by using a randomized crossover study design. The additions of metronidazole, clindamycin, and ornidazole did not affect the pharmacokinetics of the quinolones. The combination of clindamycin with ciprofloxacin, ofloxacin, and, to a lesser extent, fleroxacin resulted in an increase of the SBA against gram-positive strains (mean peak titers): Staphylococcus aureus, ciprofloxacin alone, 1:5.5; ciprofloxacin-clindamycin, 1:19.9; ofloxacin alone, 1:3.6; ofloxacin-clindamycin, 1:17.5; fleroxacin alone, 1:4.3; fleroxacin-clindamycin, 1:8.1; Streptococcus pneumoniae (fleroxacin and enoxacin were not tested), ciprofloxacin alone, 1:2.0; ciprofloxacin-clindamycin, 1:53; ofloxacin alone, 1:2.6; and ofloxacin-clindamycin, 1:49.2. The high SBA of quinolones against gram-negative bacteria was not affected by the combinations; however, relatively low activities against Pseudomonas aeruginosa were detected. In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9). In clinical settings with severe mixed infections, a parenteral therapy consisting of modern quinolones together with clindamycin or imidazole derivatives seems to be active and offers no obvious interactions.
机译:为了增强喹诺酮类药物对厌氧生物和革兰氏阳性细菌的抗菌谱,我们在两项研究中研究了环丙沙星(200毫克)和氧氟沙星(200毫克)与甲硝唑(500毫克)或克林霉素(600毫克)的肠胃外联合用药,以及依诺沙星(400毫克)和氟罗沙星(400毫克)与甲硝唑(400毫克),克林霉素(300毫克)或奥硝唑(500毫克)的口服组合(仅与氟罗沙星)。通过使用随机交叉研究设计,在两组10名健康志愿者中确定了针对5种需氧菌和2种厌氧菌(共58株)的药代动力学和血清杀菌活性(SBA)。甲硝唑,克林霉素和奥硝唑的添加不会影响喹诺酮类药物的药代动力学。克林霉素与环丙沙星,氧氟沙星的组合,以及在较小程度上与氟沙星的组合,导致针对革兰氏阳性菌株的SBA升高(平均峰值滴度):金黄色葡萄球菌,环丙沙星单独,1:5.5;环丙沙星-克林霉素,1:19.9;单独使用氧氟沙星,1:3.6;氧氟沙星-克林霉素,1:17.5;单独使用氟沙星,1:4.3;氟沙星-克林霉素,1:8.1;肺炎链球菌(未测试氟罗沙星和依诺沙星),环丙沙星单独使用,1:2.0;环丙沙星-克林霉素,1:53;单独使用氧氟沙星,1:2.6;氧氟沙星-克林霉素,1:49.2。喹诺酮类对革兰氏阴性菌的高SBA不受组合的影响。然而,检测到针对铜绿假单胞菌的活性相对较低。通常,在两项研究中,针对厌氧细菌的杀菌活性均较低(平均滴度范围为1:2.1至1:3.1;平均槽滴度范围为1:2.0至1:2.9)。在严重混合感染的临床环境中,由现代喹诺酮类药物与克林霉素或咪唑衍生物组成的肠胃外治疗似乎很活跃,并且没有明显的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号